Fig. 4

Identification of new co-regulated pathways in MAPKi treated pLGG cells. a Heatmap depicting the filtered signatures considered to be consistently regulated upon MAPKi treatment (trametinib 100 nM) in the senescent DKFZ-BT66 cells through omics layers. RNAseq = signature from RNAseq dataset, Prot = signatures from proteomics dataset. PhosProt = signatures from phosphoproteomics dataset. b Sunburst chart summarizing the signaling pathways upregulated (UP) and downregulated (DN) upon MAPKi (trametinib 100 nM) in the senescent DKFZ-BT66 cells. The inner circle represents the proportion (sections’ length) of signatures belonging to a given category relative to the total amount of signatures belonging to that category, while the outer circle represents the proportion (bars’ height) of signatures belonging to a given sub-category relative to the total amount of signatures belonging to that sub-category. c Butterfly plot depicting the results from the GSEA comparing RNAseq expression of the 100 nM trametinib 24 h samples and control, using the HALLMARK gene set. Only the signatures with an FDR q-val < 0.25 are depicted. NES normalized enrichment score, FDR false discovery rate. d Heatmap depicting the scaled peptide abundance of top 20 most upregulated proteins related to interferon activity and participating in the core enrichment of the HALLMARK signatures related to interferon alpha and gamma in the RNAseq data from (c)